Waiting times in early-stage Non-small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

Volumn 3, Issue 8, 2008, Pages 865-870

  Saint Jacques, Nathalie ^a   Rayson, Daniel ^b,c   Al Fayea, Turki ^b,c   Virik, Kiran ^b,c   Morzycki, Wojciech ^b,c   Younis, Tallal ^b,c  

^a Cancer Care Nova Scotia   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Adjuvant chemotherapy; Elapsed times; Non small cell lung cancer; Waiting times

Indexed keywords

ADULT; AGED; ARTICLE; CANADA; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CONSULTATION; DEMOGRAPHY; FEMALE; HOSPITAL ADMISSION; HUMAN; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MALE; MEDICAL RECORD REVIEW; ONCOLOGY; PATIENT REFERRAL; PATIENT SCHEDULING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ADJUVANT CHEMOTHERAPY; COHORT ANALYSIS; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; SMOKING; STATISTICS; TIME;

CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SMOKING; TIME FACTORS; WAITING LISTS;

EID: 58149106256     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318180210c     Document Type: Article

References (27)

1. Lewis S, Barer ML, Sanmartin C, Shep S, Shortt SE, McDonald PW. Ending waiting-list mismanagement: principles and practice. CMAJ 2000;162:1297-1300.
2. Sanmartin C, Shortt S, Barer ML, Sheps S, Lewis S, McDonald PW. Waiting for medical services in Canada: lots of heat, but little light. CMAJ 2000;162:1305-1310.
3. Canadian Institute for Health Information. Waiting for health care in Canada: what we know and what we don't know. Ottawa: Canadian Institute for Health Information 2006.
4. Norris S. Science and Technology Division. The wait times issue: a snapshot. Ottawa, Canada: Library of Parliament, 2006.PRB 05-82E.
5. Canadian Institute for Health Information. Analysis in brief: taking health information further. Wait times tables - a comparison by province, 2007. Ottawa: Canadian Institute for Health Information 2007.
6. Wait Time Alliance for Timely Access to Health Care. Time's up! Achieving meaningful reductions in wait times. Progress report. Ottawa: Canadian Medical Association, 2007.
7. Lo DS, Zeldin RA, Skrastins R, et al. Time to treat: a system redesign focusing on decreasing the time from suspicion of lung cancer to diagnosis. J Thorac Oncol 2007;2:1001-1006.
8. Rayson D, Chaisson D, Dewar R. Elapsed time from breast cancer detection to first adjuvant therapy in a Canadian province, 1999-2000. CMAJ 2004;170:957-961.
9. Rayson D, Saint-Jacques N, Younis T, Meadows J, Dewar R. Comparison of elapsed times from breast cancer detection to first adjuvant therapy in Nova Scotia in 1999/2000 and 2003/2004. CMAJ 2007;176: 327-332.
10. Saint-Jacques N, Younis T, Dewar R, Rayson D. Wait times for breast cancer care. Br J Cancer 2007;96:162-168.
11. Canadian Cancer Society, National Cancer Institute of Canada. Canadian Cancer Statistics, 2007. Toronto, Canada: Canadian Cancer Society 2007.
12. Ginsberg RJ, Vokes EE, Raben A. Principles and Practice of Oncology, 5th Ed. Philadelphia: Lippincott-Raven 1997. Pp. 858-1911.
13. Seer: Surveillance, Epidemiology, and End Results Program, National Cancer Institute. Cancer Statistics, 2005. Available at: http://seer.cancer. gov/. Accessed June 25, 2008.
14. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-1717.
15. Douillard J, Rosell R, De Lena M, et al. ANITA: phase III adjuvant vinorelbine and cisplatin versus observation in completely resected (Stage I-III) non-small cell lung cancer patients: final results after 70 month median follow-up. J Clin Oncol 2005;23(Suppl 165):624S.
16. Strauss CM, Herndon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage1B non-small-cell lung cancer: report of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 2004; 22(Suppl 145):621S.
17. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. Observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-2597.
18. The International Adjuvant Lung Cancer Trial (IALT) Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 2004;350: 351-360.
19. Christensen ED, Harvald T, Jendresen M, Aggestrup S, Petterson G. The impact of delayed diagnosis of lung cancer on the stage at the time of operation. Eur J Cardiothorac Surg 1997;12:880-884.
20. Moody A, Muers M, Forman D. Delays in managing lung cancer. Thorax 2004;59:1-3.
21. Aragoneses FG, Moreno N, Leon P, Fontan EG, Folque E. Influence of delays on survival in the surgical treatment of bronchogenic carcinoma. Lung Cancer 2002;36:59-63.
22. Billing JS, Wells FC. Delays in the diagnosis and surgical treatment of lung cancer. Thorax 1996;51:903-906.
23. Bozcuk H, Martin C. Does treatment delay affect survival in non-small cell lung cancer? A retrospective analysis from a single UK centre. Lung Cancer 2001;34:243-252.
24. Jensen AR, Mainz J, Overgaard J. Impact of delay on diagnosis and treatment of primary lung cancer. Acta Oncol 2002;41:147-152.
25. Armitage P, Berry G. Statistical Methods in Medical Research, 3rd Ed. Oxford: Blackwell Science; 1994.
26. SAS User's Guide: Statistics, Version 9. 1. Cary, NC, USA: SAS Institute Inc. 2007.
27. R Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria: R Core Development Team 2007.